Axsome Therapeutics, Inc.AXSMNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-18.93%
↓ 261% below average
Average (39q)
11.76%
Historical baseline
Range
High:105.00%
Low:-61.69%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -18.93% |
| Q2 2025 | 10.62% |
| Q1 2025 | -18.58% |
| Q4 2024 | 21.19% |
| Q3 2024 | -8.96% |
| Q2 2024 | 35.36% |
| Q1 2024 | 19.57% |
| Q4 2023 | 7.08% |
| Q3 2023 | 39.77% |
| Q2 2023 | 15.67% |
| Q1 2023 | 21.10% |
| Q4 2022 | -1.24% |
| Q3 2022 | -5.79% |
| Q2 2022 | 25.48% |
| Q1 2022 | -8.68% |
| Q4 2021 | 4.56% |
| Q3 2021 | -9.12% |
| Q2 2021 | -12.61% |
| Q1 2021 | -4.54% |
| Q4 2020 | 17.50% |
| Q3 2020 | 40.34% |
| Q2 2020 | -61.69% |
| Q1 2020 | 43.30% |
| Q4 2019 | 21.28% |
| Q3 2019 | 43.92% |
| Q2 2019 | 44.72% |
| Q1 2019 | 6.32% |
| Q4 2018 | 18.38% |
| Q3 2018 | 8.83% |
| Q2 2018 | 16.79% |
| Q1 2018 | 5.75% |
| Q4 2017 | 0.51% |
| Q3 2017 | -10.71% |
| Q2 2017 | -16.34% |
| Q1 2017 | 3.07% |
| Q4 2016 | 4.27% |
| Q3 2016 | 5.11% |
| Q2 2016 | 17.05% |
| Q1 2016 | 105.00% |
| Q4 2015 | 44.84% |